These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

254 related articles for article (PubMed ID: 28805099)

  • 21. The effect of prior bisphosphonate exposure on the treatment response to teriparatide in clinical practice.
    Middleton ET; Steel SA; Doherty SM
    Calcif Tissue Int; 2007 Nov; 81(5):335-40. PubMed ID: 17938845
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Effects of previous antiresorptive therapy on the bone mineral density response to two years of teriparatide treatment in postmenopausal women with osteoporosis.
    Boonen S; Marin F; Obermayer-Pietsch B; Simões ME; Barker C; Glass EV; Hadji P; Lyritis G; Oertel H; Nickelsen T; McCloskey EV;
    J Clin Endocrinol Metab; 2008 Mar; 93(3):852-60. PubMed ID: 18160462
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Analysis of daily teriparatide treatment for osteoporosis in men.
    Niimi R; Kono T; Nishihara A; Hasegawa M; Matsumine A; Kono T; Sudo A
    Osteoporos Int; 2015 Apr; 26(4):1303-9. PubMed ID: 25567777
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Effects of teriparatide in postmenopausal women with osteoporosis on prior alendronate or raloxifene: differences between stopping and continuing the antiresorptive agent.
    Cosman F; Wermers RA; Recknor C; Mauck KF; Xie L; Glass EV; Krege JH
    J Clin Endocrinol Metab; 2009 Oct; 94(10):3772-80. PubMed ID: 19584192
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Effects of daily teriparatide, weekly high-dose teriparatide, or bisphosphonate on cortical and trabecular bone of vertebra and proximal femur in postmenopausal women with fragility fracture: Sub-analysis by quantitative computed tomography from the TERABIT study.
    Takahashi R; Chiba K; Okazaki N; Era M; Yokota K; Yabe Y; Kondo C; Fukuda T; Fukushima K; Kono M; Michikoshi Y; Yamada S; Iida T; Mitsumizo K; Sato S; Doi M; Watanabe K; Ota S; Shiraishi K; Yonekura A; Osaki M
    Bone; 2024 Oct; 187():117189. PubMed ID: 38960296
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Vertebral fracture risk after once-weekly teriparatide injections: follow-up study of Teriparatide Once-Weekly Efficacy Research (TOWER) trial.
    Sugimoto T; Shiraki M; Nakano T; Kishimoto H; Ito M; Fukunaga M; Hagino H; Sone T; Kuroda T; Nakamura T
    Curr Med Res Opin; 2013 Mar; 29(3):195-203. PubMed ID: 23259702
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Teriparatide in bisphosphonate-resistant osteoporosis: microarchitectural changes and clinical results after 6 and 18 months.
    Jobke B; Muche B; Burghardt AJ; Semler J; Link TM; Majumdar S
    Calcif Tissue Int; 2011 Aug; 89(2):130-9. PubMed ID: 21626160
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Impact of switching oral bisphosphonates to denosumab or daily teriparatide on the progression of radiographic joint destruction in patients with biologic-naïve rheumatoid arthritis.
    Ebina K; Hirao M; Hashimoto J; Matsuoka H; Iwahashi T; Chijimatsu R; Etani Y; Okamura G; Miyama A; Yoshikawa H
    Osteoporos Int; 2018 Jul; 29(7):1627-1636. PubMed ID: 29574517
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Daily or Cyclical Teriparatide Treatment in Women With Osteoporosis on no Prior Therapy and Women on Alendronate.
    Cosman F; Nieves JW; Zion M; Garrett P; Neubort S; Dempster D; Lindsay R
    J Clin Endocrinol Metab; 2015 Jul; 100(7):2769-76. PubMed ID: 25961136
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Usefulness of daily teriparatide treatment in elderly patients over 80 years of age.
    Niimi R; Kono T; Nishihara A; Hasegawa M; Matsumine A; Kono T; Sudo A
    Osteoporos Int; 2016 May; 27(5):1869-74. PubMed ID: 26759334
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Intravenous zoledronic acid 5 mg in the treatment of postmenopausal women with low bone density previously treated with alendronate.
    McClung M; Recker R; Miller P; Fiske D; Minkoff J; Kriegman A; Zhou W; Adera M; Davis J
    Bone; 2007 Jul; 41(1):122-8. PubMed ID: 17468062
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Impact of bisphosphonate wash-out prior to teriparatide therapy in clinical practice.
    Keel C; Kraenzlin ME; Kraenzlin CA; Müller B; Meier C
    J Bone Miner Metab; 2010; 28(1):68-76. PubMed ID: 19633810
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Three years of treatment with minodronate in patients with postmenopausal osteoporosis.
    Hagino H; Shiraki M; Fukunaga M; Nakano T; Takaoka K; Ohashi Y; Nakamura T; Matsumoto T
    J Bone Miner Metab; 2012 Jul; 30(4):439-46. PubMed ID: 22134624
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Efficacy and safety of minodronate in the treatment of postmenopausal osteoporosis with low back pain: a single-centre, randomized and open-label controlled trial.
    Wang H; Huang J; Tao L; Liu D; Song C
    Trials; 2024 Aug; 25(1):534. PubMed ID: 39135126
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Change in arterial stiffness associated with monthly bisphosphonate treatment in women with postmenopausal osteoporosis.
    Igase M; Kohara K; Tabara Y; Ohara M; Takita R; Ochi M; Okada Y; Miki T
    Menopause; 2014 Sep; 21(9):962-6. PubMed ID: 24552979
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Bisphosphonate Pre-Treatment Diminishes the Therapeutic Benefits of Teriparatide in Japanese Osteoporotic Patients.
    Kamimura M; Nakamura Y; Ikegami S; Uchiyama S; Kato H
    Tohoku J Exp Med; 2016 May; 239(1):17-24. PubMed ID: 27150954
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Initiation of Monthly Minodronate Therapy at an Early Stage After Hip Fracture.
    Ohishi T; Fujita T; Suzuki D; Nishida T; Okabayashi R; Yamamoto K; Ushirozako H; Banno T; Matsuyama Y
    J Clin Densitom; 2016; 19(3):352-8. PubMed ID: 27067298
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Frequency of discontinuation of injectable osteoporosis therapies in US patients over 2 years.
    Modi A; Sajjan S; Insinga R; Weaver J; Lewiecki EM; Harris ST
    Osteoporos Int; 2017 Apr; 28(4):1355-1363. PubMed ID: 28058444
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Clinical efficacy and treatment persistence of monthly minodronate for osteoporotic patients unsatisfied with, and shifted from, daily or weekly bisphosphonates: the BP-MUSASHI study.
    Sakai A; Ikeda S; Okimoto N; Matsumoto H; Teshima K; Okazaki Y; Fukuda F; Arita S; Tsurukami H; Nagashima M; Yoshioka T
    Osteoporos Int; 2014 Sep; 25(9):2245-53. PubMed ID: 24899103
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Combination teriparatide and raloxifene therapy for postmenopausal osteoporosis: results from a 6-month double-blind placebo-controlled trial.
    Deal C; Omizo M; Schwartz EN; Eriksen EF; Cantor P; Wang J; Glass EV; Myers SL; Krege JH
    J Bone Miner Res; 2005 Nov; 20(11):1905-11. PubMed ID: 16234962
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 13.